Appeals court revives lawsuits claiming link between acetaminophen, ADHD and autism
A federal appeals court on Monday revived hundreds of lawsuits where plaintiffs claimed to have evidence of a link between acetaminophen and neurodevelopmental disorders. The 2nd U.S. Circuit Court of
A federal appeals court on Monday revived hundreds of lawsuits where plaintiffs claimed to have evidence of a link between acetaminophen and neurodeve
Read Full Story at The Hill →Why This Matters
The revival of these lawsuits underscores a growing public distrust in regulatory oversight of over-the-counter medications, particularly when scientific consensus remains unsettled. It also signals a potential shift in how courts handle claims tying common pharmaceuticals to long-term health risks, which could set a precedent for future litigation involving widely used drugs.
Background Context
Acetaminophen, the active ingredient in Tylenol, has been a staple of pain and fever management for decades, with its safety profile largely unchallenged despite limited long-term studies on neurodevelopmental effects. The lawsuits hinge on emerging but contested research suggesting prenatal or early-childhood exposure could elevate risks of ADHD and autism, a hypothesis that regulators have yet to fully endorse or dismiss.
What Happens Next
Legal experts anticipate a prolonged battle over scientific evidence, with both sides likely to present conflicting expert testimony on causality and risk thresholds. The court’s decision to revive these cases may embolden further litigation, while pharmaceutical companies could face heightened scrutiny over labeling and consumer warnings. If plaintiffs gain traction, it could spur regulatory re-evaluations of acetaminophen’s safety margins.
Bigger Picture
This case reflects a broader trend where courts are increasingly becoming arbiters of medical uncertainty, often filling gaps left by agencies slow to act on emerging health concerns. It also highlights how mass tort litigation is evolving to target substances once considered benign, raising questions about the balance between corporate liability and public access to essential medications.
